| . | All (N = 103) . | CKD = 3 (N = 56) . | CKD = 4 (N = 47) . | P-valuea . |
|---|---|---|---|---|
| Sex female, N (%) | 51 (49.5%) | 29 (51.8%) | 22 (46.8%) | 0.76 |
| Age, years, mean (SD) | 67.0 (11.0) | 66.1 (12.2) | 68.0 (9.33) | 0.373 |
| Ethnicity Caucasian, N (%) | 88 (85.4%) | 50 (89.3%) | 38 (80.9%) | 0.353 |
| BMI, kg/m2 mean (SD) | 31.5 (7.17) | 30.7 (6.27) | 32.5 (8.08) | 0.213 |
| Hypertension,bN (%) | 102.0 (99.0%) | 56.0 (100%) | 46.0 (97.9%) | 0.456 |
| Diabetes mellituscN (%) | 54.0 (52.4%) | 28.0 (50.0%) | 26.0 (55.3%) | 0.734 |
| Smokersd, N (%) | 58 (56.3%) | 31 (55.4%) | 27 (57.4%) | 0.99 |
| LDL-cholesterol,e mg/dL, mean (SD) | 95.5 (32.9) | 91.7 (28.7) | 100.0 (37.1) | 0.215 |
| Systolic BP, mmHg, mean (SD) | 127 (16.1) | 124 (15.1) | 130 (16.9) | 0.111 |
| eGFR, mL/min/1.73 m2, mean (SD) | 31.2 (8.39) | 37.2 (6.17) | 24.0 (3.53) | <0.001 |
| CAC volume score,f mm3, median [1st quartile; 3rd quartile] | 234.0 [43.0; 737] | 222.0 [79.2; 738] | 246.0 [27.0; 661] | 0.768 |
| AAC volume score,f mm3, median [1st quartile; 3rd quartile] | 1623 [258; 5377] | 1254 [269; 5114] | 2030 [212; 5377] | 0.478 |
| TAC volume score,g mm3, median [1st quartile; 3rd quartile] | 501 [104; 2104] | 418 [74.0; 2083] | 867 [150; 2040] | 0.476 |
| Patients with measurable AAC volume score at baseline, N (%) | 81 (87.1%) | 45 (86.5%) | 36 (87.8%) | 0.99 |
| Patients with measurable CAC volume score at baseline, N (%) | 78 (83.9%) | 46 (88.5%) | 32 (78%) | 0.284 |
| Patients with measurable TAC volume score at baseline, N (%) | 65 (82.3%) | 36 (81.8%) | 29 (82.9%) | 0.99 |
| . | All (N = 103) . | CKD = 3 (N = 56) . | CKD = 4 (N = 47) . | P-valuea . |
|---|---|---|---|---|
| Sex female, N (%) | 51 (49.5%) | 29 (51.8%) | 22 (46.8%) | 0.76 |
| Age, years, mean (SD) | 67.0 (11.0) | 66.1 (12.2) | 68.0 (9.33) | 0.373 |
| Ethnicity Caucasian, N (%) | 88 (85.4%) | 50 (89.3%) | 38 (80.9%) | 0.353 |
| BMI, kg/m2 mean (SD) | 31.5 (7.17) | 30.7 (6.27) | 32.5 (8.08) | 0.213 |
| Hypertension,bN (%) | 102.0 (99.0%) | 56.0 (100%) | 46.0 (97.9%) | 0.456 |
| Diabetes mellituscN (%) | 54.0 (52.4%) | 28.0 (50.0%) | 26.0 (55.3%) | 0.734 |
| Smokersd, N (%) | 58 (56.3%) | 31 (55.4%) | 27 (57.4%) | 0.99 |
| LDL-cholesterol,e mg/dL, mean (SD) | 95.5 (32.9) | 91.7 (28.7) | 100.0 (37.1) | 0.215 |
| Systolic BP, mmHg, mean (SD) | 127 (16.1) | 124 (15.1) | 130 (16.9) | 0.111 |
| eGFR, mL/min/1.73 m2, mean (SD) | 31.2 (8.39) | 37.2 (6.17) | 24.0 (3.53) | <0.001 |
| CAC volume score,f mm3, median [1st quartile; 3rd quartile] | 234.0 [43.0; 737] | 222.0 [79.2; 738] | 246.0 [27.0; 661] | 0.768 |
| AAC volume score,f mm3, median [1st quartile; 3rd quartile] | 1623 [258; 5377] | 1254 [269; 5114] | 2030 [212; 5377] | 0.478 |
| TAC volume score,g mm3, median [1st quartile; 3rd quartile] | 501 [104; 2104] | 418 [74.0; 2083] | 867 [150; 2040] | 0.476 |
| Patients with measurable AAC volume score at baseline, N (%) | 81 (87.1%) | 45 (86.5%) | 36 (87.8%) | 0.99 |
| Patients with measurable CAC volume score at baseline, N (%) | 78 (83.9%) | 46 (88.5%) | 32 (78%) | 0.284 |
| Patients with measurable TAC volume score at baseline, N (%) | 65 (82.3%) | 36 (81.8%) | 29 (82.9%) | 0.99 |
aP-value for the comparison of CKD Stage 3 with CKD Stage 4.
bMeasured in patients with hypertension only.
cMeasured in patients with diabetes mellitus only.
dSmokers include patients who currently smoke or have ever smoked.
eN = 102.
fN = 93.
gN = 79.
| . | All (N = 103) . | CKD = 3 (N = 56) . | CKD = 4 (N = 47) . | P-valuea . |
|---|---|---|---|---|
| Sex female, N (%) | 51 (49.5%) | 29 (51.8%) | 22 (46.8%) | 0.76 |
| Age, years, mean (SD) | 67.0 (11.0) | 66.1 (12.2) | 68.0 (9.33) | 0.373 |
| Ethnicity Caucasian, N (%) | 88 (85.4%) | 50 (89.3%) | 38 (80.9%) | 0.353 |
| BMI, kg/m2 mean (SD) | 31.5 (7.17) | 30.7 (6.27) | 32.5 (8.08) | 0.213 |
| Hypertension,bN (%) | 102.0 (99.0%) | 56.0 (100%) | 46.0 (97.9%) | 0.456 |
| Diabetes mellituscN (%) | 54.0 (52.4%) | 28.0 (50.0%) | 26.0 (55.3%) | 0.734 |
| Smokersd, N (%) | 58 (56.3%) | 31 (55.4%) | 27 (57.4%) | 0.99 |
| LDL-cholesterol,e mg/dL, mean (SD) | 95.5 (32.9) | 91.7 (28.7) | 100.0 (37.1) | 0.215 |
| Systolic BP, mmHg, mean (SD) | 127 (16.1) | 124 (15.1) | 130 (16.9) | 0.111 |
| eGFR, mL/min/1.73 m2, mean (SD) | 31.2 (8.39) | 37.2 (6.17) | 24.0 (3.53) | <0.001 |
| CAC volume score,f mm3, median [1st quartile; 3rd quartile] | 234.0 [43.0; 737] | 222.0 [79.2; 738] | 246.0 [27.0; 661] | 0.768 |
| AAC volume score,f mm3, median [1st quartile; 3rd quartile] | 1623 [258; 5377] | 1254 [269; 5114] | 2030 [212; 5377] | 0.478 |
| TAC volume score,g mm3, median [1st quartile; 3rd quartile] | 501 [104; 2104] | 418 [74.0; 2083] | 867 [150; 2040] | 0.476 |
| Patients with measurable AAC volume score at baseline, N (%) | 81 (87.1%) | 45 (86.5%) | 36 (87.8%) | 0.99 |
| Patients with measurable CAC volume score at baseline, N (%) | 78 (83.9%) | 46 (88.5%) | 32 (78%) | 0.284 |
| Patients with measurable TAC volume score at baseline, N (%) | 65 (82.3%) | 36 (81.8%) | 29 (82.9%) | 0.99 |
| . | All (N = 103) . | CKD = 3 (N = 56) . | CKD = 4 (N = 47) . | P-valuea . |
|---|---|---|---|---|
| Sex female, N (%) | 51 (49.5%) | 29 (51.8%) | 22 (46.8%) | 0.76 |
| Age, years, mean (SD) | 67.0 (11.0) | 66.1 (12.2) | 68.0 (9.33) | 0.373 |
| Ethnicity Caucasian, N (%) | 88 (85.4%) | 50 (89.3%) | 38 (80.9%) | 0.353 |
| BMI, kg/m2 mean (SD) | 31.5 (7.17) | 30.7 (6.27) | 32.5 (8.08) | 0.213 |
| Hypertension,bN (%) | 102.0 (99.0%) | 56.0 (100%) | 46.0 (97.9%) | 0.456 |
| Diabetes mellituscN (%) | 54.0 (52.4%) | 28.0 (50.0%) | 26.0 (55.3%) | 0.734 |
| Smokersd, N (%) | 58 (56.3%) | 31 (55.4%) | 27 (57.4%) | 0.99 |
| LDL-cholesterol,e mg/dL, mean (SD) | 95.5 (32.9) | 91.7 (28.7) | 100.0 (37.1) | 0.215 |
| Systolic BP, mmHg, mean (SD) | 127 (16.1) | 124 (15.1) | 130 (16.9) | 0.111 |
| eGFR, mL/min/1.73 m2, mean (SD) | 31.2 (8.39) | 37.2 (6.17) | 24.0 (3.53) | <0.001 |
| CAC volume score,f mm3, median [1st quartile; 3rd quartile] | 234.0 [43.0; 737] | 222.0 [79.2; 738] | 246.0 [27.0; 661] | 0.768 |
| AAC volume score,f mm3, median [1st quartile; 3rd quartile] | 1623 [258; 5377] | 1254 [269; 5114] | 2030 [212; 5377] | 0.478 |
| TAC volume score,g mm3, median [1st quartile; 3rd quartile] | 501 [104; 2104] | 418 [74.0; 2083] | 867 [150; 2040] | 0.476 |
| Patients with measurable AAC volume score at baseline, N (%) | 81 (87.1%) | 45 (86.5%) | 36 (87.8%) | 0.99 |
| Patients with measurable CAC volume score at baseline, N (%) | 78 (83.9%) | 46 (88.5%) | 32 (78%) | 0.284 |
| Patients with measurable TAC volume score at baseline, N (%) | 65 (82.3%) | 36 (81.8%) | 29 (82.9%) | 0.99 |
aP-value for the comparison of CKD Stage 3 with CKD Stage 4.
bMeasured in patients with hypertension only.
cMeasured in patients with diabetes mellitus only.
dSmokers include patients who currently smoke or have ever smoked.
eN = 102.
fN = 93.
gN = 79.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
